申请人:ANNJI PHARMACEUTICAL CO., LTD.
                            
                            
                                公开号:US20130281451A1
                            
                            
                                公开(公告)日:2013-10-24
                            
                            A novel class of indoline-2-one derivatives are disclosed. These compounds are protein kinase inhibitors which are useful for treating hyperproliferative diseases such as cancer.
                            揭示了一类新型的
吲哚啉-2-酮衍
生物。这些化合物是蛋白激酶
抑制剂,可用于治疗癌症等过度增殖性疾病。